Observational studyMedicine2026
Secukinumab compared to ixekizumab in biologic-naïve Chinese individuals afflicted with moderate-to-severe plaque psoriasis: A retrospective single-center analysis.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical benefits of interleukin (IL)-17A therapies for psoriasis are well-substantiated. However, efficacy outcomes for moderate-to-severe plaque psoriasis (pPS) may vary across IL-17A treatments. Practitioners require evidence to guide treatment selection within the IL-17A class for biologic-naïve patients with moderate-to-severe pPS. This study compares the effectiveness and safety of ixekizumab and secukinumab in such patients. A retrospective analysis of 5 years of electronic medical records (demographics, clinical characteristics, treatment outcomes, and adverse effects) was conducted on biologic-naïve patients receiving IL-17A treatments for moderate-to-severe stable pPS. The study comprised 70 ixekizumab users (ET cohort) and 55 secukinumab users (SB cohort) from a single center. Concurrent therapies were evenly distributed across groups. Both cohorts exhibited significant reductions in percentage body surface area involvement and Psoriasis Area and Severity Index scores posttreatment (P < .001 for all). However, the SB cohort demonstrated greater reductions in percentage body surface area involvement (P < .001) and Psoriasis Area and Severity Index scores compared with the ET cohort. Physician Global Assessment of treatment response favored the SB cohort (1.1 [1.4-1] vs 1.1 [1.5-1]). Systemic organ infections were more prevalent in the SB cohort (P = .009). Following treatment, 26 (37%) and 24 (44%) patients in the ET and SB cohorts, respectively, achieved mild disease activity (≤1 on Physician Global Assessment). The SB cohort experienced a higher incidence of adverse effects (P < .001, risk ratio = 0.52; 95% confidence interval = 0.37-0.73, I2 = 0%). In Chinese biologic-naïve patients with moderate-to-severe pPS, secukinumab may be associated with a superior response but a higher incidence of adverse effects compared with ixekizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.